APC 8015

Known as: APC-8015, APC8015, APC8015 Vaccine 
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2015
024620002015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
  • Robert Bok
  • Therapeutics and clinical risk management
  • 2008
The body's immune system has some capacity to recognize and attack cancerous growths, including prostate cancer. However, various… (More)
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2006
Review
2006
  • Drugs in R&D
  • 2006
Sipuleucel-T [APC 8015, Provenge] is an autologous, dendritic cell-based vaccine under development with Dendreon Corporation for… (More)
Is this relevant?
2005
2005
BACKGROUND Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Prostate cancer is the most commonly diagnosed malignancy in American men, yet treatment of its metastatic androgen… (More)
Is this relevant?
2004
2004
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express… (More)
Is this relevant?
Review
2002
Review
2002
Dendreon (formerly Activated Cell Therapy), in association with the Mayo Clinic, is developing the dendritic cell therapy APC… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
We attempted to induce therapeutic immunity against prostate-derived tissues in patients suffering from progressive hormone… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?